Xtant Medical Holdings, Inc. (XTNT) is a Montana-based medical device company selling orthobiologics and spinal implant systems, listed on NYSE American. As a micro-cap with limited Street coverage, its analyst universe is small. The current, attributable price targets I verified span roughly $0.60 to $1.50. BTIG's Ryan Zimmerman holds a $1.00 target (reiterated May 2026), Craig-Hallum carries $0.60 (lowered from $1.20 in August 2026), Lucid Capital Markets initiated coverage with a $1.00 target in September 2026, and Maxim Group's $1.50 stands at the top of the range. Averaging these targets yields roughly $1.03, which I round to $1.00 for readability.
The analyst consensus is uniformly bullish, yet the spread between the lowest and highest analyst price target is more than 150%, underscoring how divergent the base-case assumptions are. The bearish-end $0.60 reflects a substantial markdown tied to reduced growth and profitability assumptions, while the $1.50 high assumes a more aggressive revenue recovery. No single target should be treated as more likely than another; the mean is a reference point, not a guarantee.
After reporting third-quarter 2026 results in November 2026, XTNT fell sharply, with the latest verified close near $0.21 and an intraday low of $0.17, matching the stock's 52-week low. Reaching the $1.00 average analyst price target would therefore require upside of approximately 376% — a very large move by any standard. The company reported quarterly revenue of about $24.3 million, below estimates, and withdrew its full-year 2026 guidance, citing year-to-date performance. Trailing revenue is roughly $109 million against a market capitalization of only about $29 million to $38 million, and the company remains unprofitable, with negative EPS (earnings per share) over the trailing twelve months.
A move toward $1.00 would almost certainly depend on a re-acceleration of revenue, a return to positive earnings, and renewed confidence in management's growth roadmap — none of which is currently reflected in the depressed share price.
Several verified factors could underpin a recovery. The company has broadened its product portfolio through an exclusive distribution agreement for Dilon Technologies' HEMOBLAST Bellows hemostatic powder and a BioHorizons partnership aimed at expanding its growth-factor technology into the dental market. Gross margins remain healthy in the high-50% to low-60% range, and BTIG's valuation work notes the stock trades at a discount to diversified small- and mid-cap musculoskeletal medtech peers on an EV/Sales (enterprise value to sales) basis. A return to growth or a resumption of formal guidance could trigger positive analyst revisions and expand the stock's compressed multiple. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The obstacles are substantial. The withdrawal of full-year 2026 guidance signals weakened visibility, and the third-quarter revenue miss points to softer demand than modeled. The company remains loss-making, with negative trailing EPS and negative EBITDA (earnings before interest, taxes, depreciation, and amortization). Its micro-cap size and thin liquidity amplify volatility, as shown by the single-day decline of more than 20% in November 2026. Macroeconomic pressure on hospital capital budgets and competitive intensity in spine and orthobiologics could further delay any turnaround, keeping valuation compression intact.
The stock's technical picture reflects a steep downtrend. The 52-week range of $0.17 to $0.84 shows shares trading near the bottom of that band. The $0.17 area now acts as a key support level, while the prior high near $0.84 and the psychological $1.00 mark represent significant resistance levels on any recovery path. A durable trend reversal would require reclaiming higher ground well above the recent lows before the $1.00 objective becomes technically relevant.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always disclose a precise timeframe. Investors should watch for the next quarterly earnings release and any restated guidance, analyst rating and target revisions, the integration and revenue contribution of the HEMOBLAST Bellows and BioHorizons agreements, gross-margin trends, and cash-burn trajectory. Sector-level demand for elective spine procedures and hospital purchasing patterns also matter for this market outlook.
The $1.00 target for XTNT is the rounded mean of a small set of bullish analyst targets spanning $0.60 to $1.50. From roughly $0.21, the required upside of about 376% is very large and depends on a fundamental turnaround — renewed revenue growth, a path to profitability, and restored guidance — none of which is currently evident after the November 2026 guidance withdrawal. The discount valuation, product-line expansion, and unanimous Buy ratings provide a supportive backdrop, but losses, weak visibility, and extreme volatility are formidable obstacles. Investors should monitor the next earnings report, any guidance update, and analyst revisions before drawing conclusions, and no outcome toward or away from $1.00 is guaranteed.
For traders seeking an efficient way to monitor developments in names like XTNT, Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover new opportunities, track existing positions, and spot shifting trends more quickly than manual screening allows. It can serve as a useful complement to fundamental research when evaluating fast-moving micro-cap situations. I have found it helpful for staying on top of signals in volatile names like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTNT advanced for three days, in 195 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
XTNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTNT as a result. In 77 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for XTNT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for XTNT entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.015) is normal, around the industry mean (4.142). P/E Ratio (-3.618) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.426) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. XTNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of surgical products
Industry MedicalNursingServices